Legend Biotech Corporation (NASDAQ: LEGN) continues to be a focal point in the biotechnology sector, recognized as a top-tier player in the healthcare space. However, the stock has recently been subject to a series of mixed analyst actions and price target adjustments, creating a nuanced picture for investors. While some firms have lowered their near-term expectations, others, like Barclays, are emphasizing the company's compelling long-term trajectory and the strength of its commercial foundation.
Barclays Adjusts Price Target but Maintains Overweight Rating
In a note published on February 4, as reported by TheFly, Barclays made a strategic adjustment to its valuation of Legend Biotech. The firm lowered its price target on LEGN to $80 from $90 , while simultaneously reiterating its Overweight rating on the shares. This move signals that while Barclays sees near-term headwinds or recalibrated expectations, its fundamental conviction in the company's long-term potential remains intact.
The revision came as part of Barclays' broader Q4 earnings preview for the biotechnology industry, which involved a larger-scale reconsideration of near-term financial projections across the sector. Importantly, the analyst clarified that the long-term forecast for Legend's clinical pipeline and commercial prospects is still viewed favorably. The adjustment appears to be a tactical recalibration based on timing and near-term financial modeling rather than a deterioration of the company's underlying business prospects.
A Mixed Bag of Analyst Actions
Barclays' measured stance stands in contrast to some other recent analyst moves, which have been more bearish. Earlier in the month, H.C. Wainwright lowered its price target on Legend Biotech to $50 from $60. Even more notably, TD Cowen downgraded the stock to Hold from Buy , setting a price target of just $21. These divergent views highlight the uncertainty and differing opinions on Wall Street regarding Legend's near-term valuation and pace of growth.
CARVYKTY Continues to Dominate as Commercial Engine
Despite the mixed analyst sentiment, Legend Biotech's commercial execution remains a story of strength. In a strategic update on January 12, and following preliminary financial disclosures on January 21, the company painted a picture of robust growth. As of early 2026, CARVYKTI , its BCMA-directed CAR-T cell therapy for multiple myeloma, has solidified its position as the market leader in its class, having treated over 10,000 patients to date.
For the quarter ended December 31, 2025, Legend reported preliminary net trade sales of approximately $555 million for CARVYKTI, underscoring the therapy's rapid uptake and significant revenue-generating potential. The company has set ambitious strategic targets for 2026, aiming to leverage the global success of CARVYKTI and its broader CAR-T platform to achieve profitability by the end of the year. This goal will be driven by continued expansion in multiple myeloma, including efforts to move CARVYKTI into frontline treatment settings, as well as advancing next-generation initiatives in both in vivo and allogeneic cell therapies.
A Strong Balance Sheet to Fuel Ambition
Supporting these ambitious goals is a solid financial foundation. As of September 30, 2025, Legend Biotech reported approximately $1.0 billion in cash, cash equivalents, and time deposits. This substantial capital position provides the company with a financial runway that extends beyond 2026 , ensuring it has the resources to support its transformative growth initiatives and its pursuit of organizational operating profit.
Board Changes and Corporate Developments
Adding to the corporate activity, Legend Biotech announced a board shakeup last month. Robin Meng, the chairman and executive director of major shareholder GenScript, was appointed as a Class III director, serving until the company's 2026 annual general meeting. He replaces outgoing director Li Zhu. Directors Li Zhu and Yau Wai Man Philip resigned from the board, with the company stating that their departures were not related to any dispute over company operations or policies, suggesting an orderly transition.
A Pioneer in Next-Generation Cell Therapy
Legend Biotech Corporation is a U.S.-based biotechnology innovator at the forefront of developing next-generation cell therapies. The company is perhaps best known for its FDA-approved CAR-T treatment for multiple myeloma, but its ambition extends far beyond a single product. Legend is actively advancing cutting-edge immune-based platforms and proprietary technologies designed to redefine cancer care across multiple indications. As a clinical-stage biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of novel therapies, Legend Biotech is positioning itself as a global leader in the fight against cancer.
Barclays Adjusts Price Target but Maintains Overweight Rating
In a note published on February 4, as reported by TheFly, Barclays made a strategic adjustment to its valuation of Legend Biotech. The firm lowered its price target on LEGN to $80 from $90 , while simultaneously reiterating its Overweight rating on the shares. This move signals that while Barclays sees near-term headwinds or recalibrated expectations, its fundamental conviction in the company's long-term potential remains intact.
The revision came as part of Barclays' broader Q4 earnings preview for the biotechnology industry, which involved a larger-scale reconsideration of near-term financial projections across the sector. Importantly, the analyst clarified that the long-term forecast for Legend's clinical pipeline and commercial prospects is still viewed favorably. The adjustment appears to be a tactical recalibration based on timing and near-term financial modeling rather than a deterioration of the company's underlying business prospects.
A Mixed Bag of Analyst Actions
Barclays' measured stance stands in contrast to some other recent analyst moves, which have been more bearish. Earlier in the month, H.C. Wainwright lowered its price target on Legend Biotech to $50 from $60. Even more notably, TD Cowen downgraded the stock to Hold from Buy , setting a price target of just $21. These divergent views highlight the uncertainty and differing opinions on Wall Street regarding Legend's near-term valuation and pace of growth.
CARVYKTY Continues to Dominate as Commercial Engine
Despite the mixed analyst sentiment, Legend Biotech's commercial execution remains a story of strength. In a strategic update on January 12, and following preliminary financial disclosures on January 21, the company painted a picture of robust growth. As of early 2026, CARVYKTI , its BCMA-directed CAR-T cell therapy for multiple myeloma, has solidified its position as the market leader in its class, having treated over 10,000 patients to date.
For the quarter ended December 31, 2025, Legend reported preliminary net trade sales of approximately $555 million for CARVYKTI, underscoring the therapy's rapid uptake and significant revenue-generating potential. The company has set ambitious strategic targets for 2026, aiming to leverage the global success of CARVYKTI and its broader CAR-T platform to achieve profitability by the end of the year. This goal will be driven by continued expansion in multiple myeloma, including efforts to move CARVYKTI into frontline treatment settings, as well as advancing next-generation initiatives in both in vivo and allogeneic cell therapies.
A Strong Balance Sheet to Fuel Ambition
Supporting these ambitious goals is a solid financial foundation. As of September 30, 2025, Legend Biotech reported approximately $1.0 billion in cash, cash equivalents, and time deposits. This substantial capital position provides the company with a financial runway that extends beyond 2026 , ensuring it has the resources to support its transformative growth initiatives and its pursuit of organizational operating profit.
Board Changes and Corporate Developments
Adding to the corporate activity, Legend Biotech announced a board shakeup last month. Robin Meng, the chairman and executive director of major shareholder GenScript, was appointed as a Class III director, serving until the company's 2026 annual general meeting. He replaces outgoing director Li Zhu. Directors Li Zhu and Yau Wai Man Philip resigned from the board, with the company stating that their departures were not related to any dispute over company operations or policies, suggesting an orderly transition.
A Pioneer in Next-Generation Cell Therapy
Legend Biotech Corporation is a U.S.-based biotechnology innovator at the forefront of developing next-generation cell therapies. The company is perhaps best known for its FDA-approved CAR-T treatment for multiple myeloma, but its ambition extends far beyond a single product. Legend is actively advancing cutting-edge immune-based platforms and proprietary technologies designed to redefine cancer care across multiple indications. As a clinical-stage biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of novel therapies, Legend Biotech is positioning itself as a global leader in the fight against cancer.
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.